<DOC>
	<DOC>NCT00866736</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.</brief_summary>
	<brief_title>A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Signed Written Informed Consent Subjects with chronic phase chronic myeloid leukemia (CML) Subjects resistant/intolerant to imatinib Subjects presenting: 1. ECOG performance status (PS) score 02 2. Adequate hepatic function 3. Adequate renal function 4. Adequate lung function Concurrent malignancy other than CML Women who are pregnant or breastfeeding Concurrent pleural effusion Uncontrolled or significant cardiovascular disease A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy. Prior therapy with dasatinib Subjects with T315I and/or F317L BCRABL point mutations</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>chronic phase myeloid leukemia</keyword>
</DOC>